CT, RECIST, and malignant pleural mesothelioma

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)


The unique growth pattern of malignant pleural. mesothelioma (MPM) presents challenges for clinical investigators assessing tumour response to treatment. Assessment of response is an important surrogate for patient benefit, particularly in phase II clinical trials. Neither the previous WHO criteria nor the more recent RECIST criteria are well suited to tumour measurement in this disease. This paper discusses uni-dimensional measurement of tumour response in pleural mesothelioma, and the development and validation of the modified RECIST criteria for MPM, which attempt to overcome some of the shortcomings of the RECIST criteria in this setting. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)online - approx 5-10pp
JournalLung Cancer
Publication statusPublished - 2005


Dive into the research topics of 'CT, RECIST, and malignant pleural mesothelioma'. Together they form a unique fingerprint.

Cite this